Related Experiment Video
Updated: Aug 30, 2025
Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
Published on: November 17, 2023
Overcoming Obstacles in Liquid Biopsy Developments for Prostate Cancer
Albert Jang1, Grant P Rauterkus2, Ulka N Vaishampayan3
1Section of Hematology and Medical Oncology, Deming Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA.
Abstract:
Prostate cancer is one of the most common malignancies in men. Over time, it can metastasize and become lethal once it exhausts hormonal therapies and transitions into castration-resistant prostate cancer (CRPC). Several therapies have been recently approved for advanced prostate cancer, but identifying biomarkers for current treatments and searching for more effective treatments are urgently needed. Liquid biopsy is a powerful tool for isolating genetic material, proteins, and whole tumor cells from the blood. In recent decades, this technology has rapidly advanced, allowing for better insights into the pathogenesis and treatment response in different stages of prostate cancer. In this review, we summarize important clinical studies involving liquid biopsies in prostate cancer with a focus on advanced disease, notably regarding circulating tumor DNA, circulating tumor cells, and exosomes. We highlight the progress and the challenges that still exist for these technologies. Finally, we discuss promising avenues that will further expand the importance of liquid biopsy in the care for prostate cancer patients.
Insights
Liquid biopsy offers new insights into advanced prostate cancer, including castration-resistant prostate cancer (CRPC). This review highlights circulating tumor DNA, cells, and exosomes for improved patient care.
Area of Science:
- Oncology
- Molecular Diagnostics
Background:
- Prostate cancer is a leading cause of cancer death in men.
- Metastatic castration-resistant prostate cancer (CRPC) presents significant treatment challenges.
- There is a critical need for biomarkers and novel therapies for advanced prostate cancer.
Purpose of the Study:
- To review clinical studies on liquid biopsies in prostate cancer, focusing on advanced stages.
- To explore the role of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes.
- To discuss the progress, challenges, and future directions of liquid biopsy in prostate cancer care.
Main Methods:
- Literature review of clinical studies involving liquid biopsies in prostate cancer.
- Focus on advanced disease and specific liquid biopsy components (ctDNA, CTCs, exosomes).
Main Results:
- Liquid biopsy technologies have advanced significantly, providing insights into prostate cancer pathogenesis and treatment response.
- ctDNA, CTCs, and exosomes are key components of liquid biopsies with diagnostic and prognostic potential.
- Progress has been made, but challenges remain in the clinical application of these technologies.
Conclusions:
- Liquid biopsy is a powerful tool for understanding and managing advanced prostate cancer, including CRPC.
- Further research and technological advancements are needed to fully integrate liquid biopsy into clinical practice.
- Liquid biopsy holds promise for personalized treatment strategies and improved outcomes for prostate cancer patients.
